-->

Company Registry

Flow Pharma Inc
Profile last edited on: 1/7/2020

Therapeutic vaccines for breast and cervical canncer
Year Founded
1998
First SBIR Year
2018
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

45 Quail Ct 300
Walnut Creek, CA 94596
   (925) 238-2300
   ir@flowpharma.com
   www.flowpharma.com
Multiple Locations:   
Congressional District:   11
County:   Contra Costa

Public Profile

Flow Pharma is structured around development of therapeutic vaccines for breast cancer and cervical cancer caused by the HPV virus. The firm's pipeline includes FlowVax triple negative Breast Cancer vaccine, and Ebola / Marburg vaccines for the DoD US Army - the latter using a powerful AI computational model and a dry powder vaccine/ patented manufacturing process, which requires no refrigeration. Unlike CAR-T, the firm's low cost, peptide formulations are non-toxic and utilize highly specific Class 1 and Class 2 epitopes to attack killer T-cells which produce an immediate positive immune response. The firm was early designed around the vaccine development platform intended to design synthetic, neoantigen based, Immuno-Oncology therapeutics. The company's platform uses artificial intelligence and deep learning to select small peptides called neoantigens on the surface of cancer cells optimal for killer T-cell attack identified by gene sequencing a patient's cancer cells, enabling patients with vaccines to treat their cancer disease.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
N/A
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 CBD $674,243
Marburg Virus Prophylactic Medical Countermeasure

Key People / Management

  Reid Rubsamen -- Founder, Board Member & Chief Executive Officer

  Thomas Brady -- Vice President of Business Development & Executive Chairman

  Stephen Farr -- Director

  Michael Heatherman -- Chief Financial Officer

  Cv Herst -- Chief Scientific Officer

  Peter Lloyd -- Chief Engineer

  Lu Wang -- General Manager

SBIR firms in the news

There are no news available.